Milestone Pharmaceuticals Inc (MIST) Stock Price, Quote & News

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology

Sector: Healthcare

Phone: 514-336-0444

Website: www.milestonepharma.com

Address:

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada

RunnerSignals Sep. 12 at 9:50 PM

$CATX $MIST $EFTY $PACS $AEVA These Comeback Kings hit rock bottom then said "watch this". Friday finishes belong to the fearless https://stocksrunner.com/news/2025-09-12-comeback-kings-rule-fridays-close

1 · Reply

thb69 Sep. 12 at 8:56 PM

$MIST paytience will be rewarded. Still here for the long game 😏

0 · Reply

WolfCola Sep. 12 at 7:53 PM

$MIST up nearly 20% in two days and still barely any call movement

0 · Reply

Lh2838 Sep. 12 at 7:35 PM

$MIST coming soon?

0 · Reply

BigMoneyLyss Sep. 12 at 5:16 PM

$MIST IT’S GETTIN MISTY IN THIS B****!

0 · Reply

Consti22 Sep. 12 at 5:10 PM

$MIST

0 · Reply

ShorterNew Sep. 12 at 4:46 PM

$MIST Thanks for posting. So they expect 4$ price share on approval which is in line with most of the posters here too.

0 · Reply

Tjcmd Sep. 12 at 4:37 PM

$MIST OW base 4, best 9… no mention of A-fib market possibility

2 · Reply

Rroper Sep. 12 at 4:36 PM

$MIST Me likes this again. Paytience

0 · Reply

Bearssuckbutt Sep. 12 at 4:05 PM

$MIST $4 hmm i need $10

0 · Reply

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 12, 2025, 7:05 AM EDT - 4 weeks ago

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Jul 18, 2025, 2:16 PM EDT - 2 months ago

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Jul 11, 2025, 2:37 PM EDT - 2 months ago

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Jul 11, 2025, 9:30 AM EDT - 2 months ago

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Jul 11, 2025, 6:01 AM EDT - 2 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:00 AM EDT - 2 months ago

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Jul 7, 2025, 10:01 AM EDT - 2 months ago

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Jun 16, 2025, 8:00 AM EDT - 3 months ago

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

May 28, 2025, 8:00 AM EDT - 3 months ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 7:04 AM EDT - 4 months ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Apr 4, 2025, 2:30 PM EDT - 5 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Mar 28, 2025, 10:24 AM EDT - 6 months ago

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

Mar 28, 2025, 7:06 AM EDT - 6 months ago

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Mar 28, 2025, 7:00 AM EDT - 6 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 21, 2025, 3:18 PM EDT - 6 months ago

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Mar 20, 2025, 8:00 AM EDT - 6 months ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Mar 13, 2025, 7:08 AM EDT - 6 months ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Mar 4, 2025, 8:00 AM EST - 6 months ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2025, 8:00 AM EST - 7 months ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 8:00 AM EST - 7 months ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Feb 11, 2025, 8:00 AM EST - 7 months ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Jan 28, 2025, 8:00 AM EST - 8 months ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Nov 12, 2024, 9:03 AM EST - 10 months ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Aug 8, 2024, 4:17 PM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

May 31, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 13, 2024, 7:15 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 8, 2024, 11:36 AM EDT - 1 year ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Mar 21, 2024, 7:14 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Feb 29, 2024, 4:01 PM EST - 1 year ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024, 4:37 PM EST - 1 year ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Jan 2, 2024, 7:06 AM EST - 1 year ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT RPID

Dec 26, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Nov 21, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 6:57 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Nov 11, 2023, 10:00 AM EST - 2 years ago

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Oct 24, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Sep 27, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 7:35 AM EDT - 2 years ago

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

Jun 20, 2023, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

RunnerSignals Sep. 12 at 9:50 PM

1 · Reply

thb69 Sep. 12 at 8:56 PM

$MIST paytience will be rewarded. Still here for the long game 😏

0 · Reply

WolfCola Sep. 12 at 7:53 PM

$MIST up nearly 20% in two days and still barely any call movement

0 · Reply

Lh2838 Sep. 12 at 7:35 PM

$MIST coming soon?

0 · Reply

BigMoneyLyss Sep. 12 at 5:16 PM

$MIST IT’S GETTIN MISTY IN THIS B****!

0 · Reply

Consti22 Sep. 12 at 5:10 PM

$MIST

0 · Reply

ShorterNew Sep. 12 at 4:46 PM

$MIST Thanks for posting. So they expect 4$ price share on approval which is in line with most of the posters here too.

0 · Reply

Tjcmd Sep. 12 at 4:37 PM

$MIST OW base 4, best 9… no mention of A-fib market possibility

2 · Reply

Rroper Sep. 12 at 4:36 PM

$MIST Me likes this again. Paytience

0 · Reply

Bearssuckbutt Sep. 12 at 4:05 PM

$MIST $4 hmm i need $10

0 · Reply

biotechbuyside Sep. 12 at 12:54 PM

$EPIX $MIST WE LIVE IN A BLUE WORLD @RegulaRandy @dindinn @Succosesteve35 @Tra123842 @drsych @bigirishyeti @marvinash @Biotech_Multibaggers @Stocks4thought @Cat_in_hat VERY VERY

0 · Reply

Consti22 Sep. 12 at 11:18 AM

$MIST 💪😎

0 · Reply

nastento Sep. 12 at 10:40 AM

$MIST perhaps management pulled their head out of their asses and will push this across the finish line. Still where tf is this afib trial? That's the money grabber. Still cautiously optimistic here

2 · Reply

lookigotmeadollar Sep. 12 at 3:39 AM

$MIST this was no coincidence they had an 11% day today… wells fargo conference was beginning of the month, h.c wainwright global investment conference just wrapped up and the following day we gain 11%. Notice the volume? triple the volume, these were big time institutional buys. this wasn’t retail putzing around grabbing some shares. steady movement up with no real dips. i’d suspect we see a price of 2.50-3.50 prior to PDUFA date, then after that it’s anyone’s guess, i definitely will be loading up some calls here soon🙏🏻

1 · Reply